Trial Profile
A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MEDI 4166 (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors MedImmune
- 28 Dec 2018 Primary endpoint (Part B: Change in glucose AUC measured up to 240 minutes after mixed meal tolerance test (MMTT) from baseline to Day 36) has not been met, according to the results published in the Diabetologia.
- 28 Dec 2018 Primary endpoint (Part B: Change in LDL-C from baseline to Day 36) has been met, according to the results published in the Diabetologia
- 28 Dec 2018 Results published in the Diabetologia